{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34488003",
  "DateCompleted": {
    "Year": "2021",
    "Month": "10",
    "Day": "18"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "12",
    "Day": "21"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "08",
        "Day": "21"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.coviro.2021.08.007",
      "S1879-6257(21)00094-8"
    ],
    "Journal": {
      "ISSN": "1879-6265",
      "JournalIssue": {
        "Volume": "50",
        "PubDate": {
          "Year": "2021",
          "Month": "Oct"
        }
      },
      "Title": "Current opinion in virology",
      "ISOAbbreviation": "Curr Opin Virol"
    },
    "ArticleTitle": "Know your enemy and know yourself - the case of SARS-CoV-2 host factors.",
    "Pagination": {
      "StartPage": "159",
      "EndPage": "170",
      "MedlinePgn": "159-170"
    },
    "Abstract": {
      "AbstractText": [
        "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the etiologic agent that causes Coronavirus Disease 2019 (COVID-19) pandemic, is a newly emerging respiratory RNA virus with exceptional transmissibility and pathogenicity. Numerous COVID-19 related studies have been fast-tracked, with the ultimate goal to end the pandemic. Here we review the major stages of SARS-CoV-2 infection cycle in cells, with specific emphasis on essential host factors. Insights into the cell biology of SARS-CoV-2 infection have accelerated the development of host-directed therapeutics, as shown by dozens of clinical trials evaluating COVID-19 treatments using host-targeting compounds."
      ],
      "CopyrightInformation": "Copyright \u00a9 2021 Elsevier B.V. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore."
          }
        ],
        "LastName": "Lee",
        "ForeName": "Wai Suet",
        "Initials": "WS"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore."
          }
        ],
        "LastName": "Yousefi",
        "ForeName": "Meisam",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore."
          }
        ],
        "LastName": "Yan",
        "ForeName": "Biaoguo",
        "Initials": "B"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore."
          }
        ],
        "LastName": "Yong",
        "ForeName": "Cythia Lingli",
        "Initials": "CL"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore. Electronic address: yawshin.ooi@duke-nus.edu.sg."
          }
        ],
        "LastName": "Ooi",
        "ForeName": "Yaw Shin",
        "Initials": "YS"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Netherlands",
    "MedlineTA": "Curr Opin Virol",
    "NlmUniqueID": "101560941",
    "ISSNLinking": "1879-6257"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "RNA, Viral"
    },
    {
      "RegistryNumber": "EC 3.4.22.15",
      "NameOfSubstance": "Cathepsin L"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "etiology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "physiology"
      ],
      "DescriptorName": "Cathepsin L"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "biosynthesis"
      ],
      "DescriptorName": "RNA, Viral"
    },
    {
      "QualifierName": [
        "genetics",
        "physiology"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Virus Assembly"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Virus Internalization"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ]
}